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Background: To investigate adherence and patient-specific factors associated with poor compliance with
osteoporosis regimens among men.
Methods: In this retrospective chart review study, we collected data on male patients with osteoporosis treated in
accordance with therapeutic recommendations. Adherence was determined by the compliance and persistence of
those patients who had been dispensed an osteoporosis regimen after an index prescription. All osteoporosis
regimens were considered equivalent for the purpose of investigating adherence.
Results: The prescriptions of 333 males met the inclusion criteria for data collection. The mean age was 68.6 ±
10.4 years. The median medication possession ratio (MPR, %) at years 1 and 2 was 90.1% (interquartile range (IQR)
19–100) and 53.7% (IQR 10.4-100), respectively; 52.3% of male patients at year 1 and 37.5% at year 2 had good
compliance (defined as a MPR≧80%). The 1- and 2-year persistence rates were 45.9% and 30.0%, respectively.
Patient-specific factors associated with poor compliance (MPR < 80%) during year 1 were first prescriptions given by
orthopedists (odds ratio (OR) = 2.67; 95% confidence interval (CI) = 1.58-4.53; adjusted OR = 2.30, 95% CI = 1.26-4.22,
p = 0.007). Male patients with rheumatoid arthritis (RA) (OR = 0.22, 95% CI = 0.06-0.78, adjusted OR = 0.19, 95% CI =
0.04-0.81, p = 0.025) and baseline bone mineral density (BMD) measurements (OR = 0.52, 95% CI = 0.32-0.85;
adjusted OR = 0.51; 95% CI = 0.28-0.93, p = 0.029) were less likely to have poor compliance.
Conclusions: Adherence to osteoporosis regimens in males was suboptimal in our study. Poor compliance was
more likely in prescription of the first anti-osteoporotic regimen by an orthopedist. Men with RA and BMD
measurements before therapy had a lower risk of non-adherence. Healthcare professionals need to target patients
with specific factors to improve adherence to osteoporotic regimens.
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The prevalence of osteoporosis and osteoporotic frac-
tures has increased worldwide during the past few de-
cades [1]. Osteoporosis and related fractures are a
common cause of morbidity and mortality in the elderly
globally [2-4]. There are significant differences in skeletal
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reproduction in any medium, provided the oraccount for differences in fracture incidence, location
and outcomes [5]. While women sought medical atten-
tion for the prevention of bone loss, men were referred
because of the presence of signs and symptoms indicat-
ing a more severe disease [6]. In Taiwan, the prevalence
of osteoporosis between 1999 and 2001 among subjects
aged 50 years or older was 1.63% for men and 11.35%
for women [7]. Although the prevalence of osteoporosis
is lower in men than in postmenopausal women globally,
the mortality and morbidity of osteoporosis among men
are higher than among women [5,8-10].
A variety of regimens including bisphosphonates, es-
trogen, selective estrogen receptor modulators, calcitonin,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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able in Taiwan for the prevention and treatment of
osteoporosis, and have demonstrated anti-fracture effi-
cacy in postmenopausal women and in men [11,12]. The
efficacy of osteoporosis medications depends on adher-
ence, which consists of both compliance and persistence.
Despite the availability of several treatment options for
osteoporosis, adherence to anti-osteoporotic therapy in
real-world practice is suboptimal and has generally been
lower than in clinical trials. In a meta-analysis of 24
studies, 40-70% of osteoporotic patients were reported
to be non-adherent [13]. Although male subjects at
an advanced age often have osteoporosis and osteo-
porotic fractures, little is known about their exact ad-
herence rates because researchers rarely include men
in osteoporosis adherence studies, [14,15] or seldom
report adherence rates separately or exclusively for men.
Non-adherence to osteoporosis regimens is clearly asso-
ciated with poorer outcomes. Therefore, it is essential to
improve drug adherence for both postmenopausal women
and osteoporotic men, so as to enhance therapeutic
outcomes.
Claims or pharmacy databases are usually used to
measure adherence and to determine factors associated
with non-adherence to osteoporosis medications. Non-
adherence in women has been previously reported to be
related to the drugs, the patients, and the doctors
[16-18]. Few studies in the literature have investigated
the factors affecting adherence among males with osteo-
porosis [14,15]. Therefore, further identification of risk
factors for non-adherence among males with osteo-
porosis may help improve adherence and ultimately
reduce fracture risk. In addition, many studies have
demonstrated that realizing the anti-fracture efficacy
of osteoporosis medications may require several years
of therapy [19,20], but most reports have investigated
adherence to anti-osteoporotic therapy within one year
only [13,21,22].
In this retrospective chart review study of male pa-
tients with osteoporosis treated at a single medical cen-
ter in southern Taiwan, we aimed to investigate 1- and
2-year adherence (both compliance and persistence) to
osteoporosis regimens (including bisphosphonates and




This was a retrospective medical chart review study. The
charts of all consecutive male subjects (aged >18 years)
who had been diagnosed with osteoporosis and had been
dispensed osteoporosis regimens between 1 January
2001 and 31 July 2007 in Chang-Gung Memorial Hos-
pital, Kaohsiung (CGMHK) Medical Center wereretrieved. Our hospital is a tertiary care referral center
located in Kaohsiung County in southern Taiwan, serv-
ing a population of about 2,000,000. The study was
conducted according to the protocol approved by the
Ethics Committee of Chang Gung Memorial Hospital
(IRB No: 97-0165C), and a waiver was granted for
obtaining informed consent.
We searched the computerized databases in CGMHK
for the following diagnostic codes (International Classifi-
cation of Diseases, Ninth Edition, Clinical Modification,
ICD-9-CM): 733.0 (osteoporosis), 733.01 (senile osteo-
porosis), 733.02 (idiopathic osteoporosis), 733.03 (disuse
osteoporosis), 733.00 (osteoporosis, unspecified), 733.09
(osteoporosis, others), 781.91 (loss of height), V17.81
(family history of osteoporosis), V82.81 (specific screen-
ing for osteoporosis), 8054 (spine fracture), and 82,100
(hip fracture). Target osteoporosis regimens included
Miacalcic® nasal spray (code: PMF022E, calcitonin 200
iu, Novartis), Fosamax® (10) (code: PMF050M, alendro-
nate, 10 mg tab, Merck Sharp & Dohme), Fosamax® (70)
(code: PMF052M, alendronate, 70 mg tab, Merck Sharp
& Dohme), and Forteo® (code: PMF042P, teriparatide, 20
mcg/shot, Eli Lilly and Company). Risedronate was not
available in Taiwan and ibandronate, zoledronic acid,
and strontium ranelate were available only after 2007 in
Taiwan. Therefore, the anti-osteoporotic agents targeted
in this study did not include these regimens.
Inclusion and exclusion criteria
Medical records of male subjects who had been dis-
pensed the above regimens under National Osteoporosis
Foundation (NOF) treatment recommendations (2008)
[23] or the American College of Rheumatology (ACR)
guidelines for glucocorticoid-induced osteoporosis (GIOP)
(2001) during the study period were reviewed [24]. Pa-
tients that did not fulfill the above inclusion criterion,
whose chart had been destroyed, who received medica-
tions for conditions other than osteoporosis, or those that
expired during the follow-up period were excluded.
Data collection
The demographic and clinical characteristics of the
study subjects, including age, gender, selected comorbid
conditions, baseline dual energy X-ray absorptiometry
(DXA), evidence of prior osteoporotic fracture, sites of
osteoporotic fracture, history of vertebroplasty, first pre-
scriber of osteoporosis regimen, and consumption of al-
cohol/smoking, were examined. Age was assessed at the
date of therapy initiation. Comorbidities documentation
(including hypertension, cardiac diseases, chronic re-
spiratory diseases, endocrine diseases, chronic kidney
disease, hepatobiliary diseases, malignant neoplasms,
neuropsychiatric disorders, and rheumatoid arthritis
[RA]) and evidence of prior osteoporotic fracture
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were ascertained on the basis of the opinion of relevant
specialists.
Calculation of adherence
Adherence, as defined by Cramer et al. [25] was evalu-
ated using the parameters of compliance and persist-
ence. Compliance was estimated by the medication
possession ratio (MPR) and persistence by the time from
treatment initiation to discontinuation with no medica-
tion refill gap for a period of 30 days or more during the
period of interest. Study patients were rated as having
good compliance if the annual MPR ≥80%. MPR was de-
fined as the ratio of actually available doses against the
expected doses that the patient should possess over a
fixed period of time. The 1-year and 2-year MPR were
defined as being the percentage of days with an available
drug supply within a predefined interval of 365 days
(year 1) or 730 days (year 2), respectively. Persistence
rate (PR) was defined as the percentage of patients that
were still on medication at a given time with no refill
gap in medication-taking for a period of 30 days or
more. The risk factors of poor compliance (MPR <80%)
were evaluated at the end of year 1. In the sub-group
analysis, we excluded those subjects with MPR <80% at
the end of year 1 and the MPR of the remaining subjects
(MPR ≥80% at year 1) were reevaluated at the end of
year 2. The corresponding risk factors were analyzed
using the logistic regression model accordingly.
Statistical methods
Patient characteristics were reported as simple descrip-
tive statistics (i.e., mean ± standard deviation [SD]). The
median (25% to 75% inter-quartile range, IQR) was used
to summarize data for continuous variables and percent-
ages with a non-normal distribution. In univariate analysis,
categorical variables were compared using the chi-square
test or Fisher's exact test. Continuous variables were com-
pared using the t-test. The cumulative distribution curves
of persistence were generated using the Kaplan-Meier
method. Multivariate analysis was performed by estimat-
ing the odds ratio (OR) and its 95% confidence interval
(CI) using a logistic regression model. All variables of
baseline characteristics with a p < 0.05 in univariate ana-
lysis were considered for inclusion in the multivariate
model. Statistical significance was defined as a p-value of
less than 0.05. All analyses were performed using the SPSS




A total of 8280 charts with predefined diagnostic codes
were retrieved. After excluding medical records thatwere not traceable, 3589 charts were reviewed. In all,
333 male subjects met the inclusion criteria for data col-
lection. The mean age of the subjects was 68.6 ±
10.4 years. Of the 333 subjects, 282 (84.7%) fulfilled the
NOF recommendation and the remaining (15.3%) ful-
filled the ACR guideline. Two thirds of the patients in
our cohort had a comorbidity of interest. The most
prevalent comorbidity among all patients was hyperten-
sion. Most of the patients (90.4%) had a baseline osteo-
porotic fracture. Vertebral fracture was the most
common (79.6%) in our cohort, followed by hip fracture
(14.4%). DXA measurement at baseline was available in
28.2% of patients. Rheumatologists and orthopaedists
were the most common (72.3 or 72.4%) first prescribers
of osteoporosis regimens. Baseline patient characteristics
in this study are shown in Table 1.
Drug adherence and patient-specific factors associated
with poor compliance
In terms of compliance, the median MPR at year 1 and
year 2 was 90.1% (IQR 19–100) and 53.7% (IQR 10.4-
100), respectively. More than half (52.3%) of the males
had good compliance (MPR ≥ 80%) at year 1, but only
37.5% through year 2. In addition, the PR of all 333 men
at year 1 and year 2 was 45.9% and 30.0%, respectively.
One-year compliance was lower with start prescriptions
by orthopedists (OR = 2.673, p = 0.000; CI, 1.58-4.53; ad-
justed OR = 2.302, CI, 1.26-4.22, p = 0.007, compared to
start prescriptions by rheumatologists). Male patients
with RA (OR = 0.22, 95% CI = 0.06-0.78, adjusted OR =
0.19, 95% CI = 0.04-0.81, p = 0.025) and baseline bone
mineral density (BMD) measurements (OR = 0.52, 95%
CI = 0.32-0.85; adjusted OR = 0.51; 95% CI = 0.28-0.93,
p = 0.029) were less likely to have poor compliance
(Table 2). There was no association between the other
baseline characteristics and poor compliance at year 1.
In addition, we also analyzed the subgroup with a
MPR ≥ 80% at year 1 to recognize the predictors of non-
adherence at year 2. Baseline patient characteristics in
the subgroup (n = 174) are shown in Table 1. No identi-
fied factor was associated with poor compliance during
year 2 in this subgroup of subjects (Table 2).
Discussion
Osteoporosis in men has been documented as a serious
health issue recently, as osteoporosis can cause higher
morbidity and mortality in men than in women, though
it affects males less frequently [5,10]. Indeed, whereas
numerous data related to the adherence of female osteo-
porosis patients are available, data are scarce for men.
To our knowledge, the present study is one of few that
have investigated the factors affecting medication com-
pliance among males with osteoporosis. The findings
were in accord with the results of our total cohort [26],
Table 1 Characteristics of the study subjects
Characteristic Total cohort Subgroup*
Number of subjects (male) 333 174
Age (y), mean ± SD 68.6 ± 10.4 67.1 ± 10.9
Comorbidity, n (%) 229 (68.8) 116 (66.7)
Comorbid diseases, n (%)
1. Hypertension 110 (33.0) 61 (35.1)
2. Neuropsychiatric 58 (17.4) 28 (16.1)
3. Cardiac 52 (15.6) 20 (11.5)
4. Endocrine/metabolic 51 (15.3) 22 (12.6)
5. Respiratory 35 (10.5) 16 (9.2)
6. Malignancy 23 (6.9) 12 (6.9)
7. Chronic kidney disease 22 (6.6) 10 (5.7)
8. Hepatobiliary 21 (6.3) 15 (8.6)
9. Rheumatoid arthritis 17 (5.1) 14 (8.0)
Fracture history, n (%) 301 (90.4) 151 (86.8)
Fracture sites, n (%)
Spine 265 (79.6) 134 (77.0)
Hip 48 (14.4) 21 (12.1)
Others@ 21 (6.3) 8 (4.6)
Baseline DXA, n (%) 94 (28.2) 60 (34.5)
BMD T-score (SD), mean ± SEM
Spine −2.0 ± 0.2 −1.9 ± 0.2
Femoral neck −2.1 ± 0.1 −1.9 ± 0.1
Total hip −1.7 ± 0.1 −1.6 ± 0.2
First prescriber, n (%)
Rheumatology 140 (42.0) 85 (48.9)
Orthopedics 101 (30.3) 37 (21.3)
Others# 92 (27.6) 52 (29.9)
Enrolment criteria
NOF recommendation, n (%) 282 (84.7) 144 (82.8)
ACR guideline, n (%) 51 (15.3) 30 (17.2)
Vertebroplasty, n (%) 11 (3.3) 6 (3.4)
Tobacco use 1 (0.3) 0 (0)
Alcohol use 2 (0.6) 1 (0.6)
*Subjects with MPR ≥ 80% at year 1; NOF (2008): Clinician's Guide to
Prevention and Treatment of Osteoporosis by the National Osteoporosis
Foundation (2008); ACR (2001): Recommendations for the treatment and
prevention of glucocorticoid-induced osteoporosis by the American College of
Rheumatology (2001); DXA: Dual energy X-ray absorptiometry; BMD: bone
mineral density; SD: standard deviation; SEM: standard error of the mean;
Serum creatinine >1.4 mg/dl; @: including rib, wrist, upper arm and pelvis;
#: Physician of Family Medicine, Metabolism, Rehabilitation.
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ence among male subjects was suboptimal. In contrast
with previous investigations of female osteoporosis, our
survey revealed the major risk factors of poor compli-
ance at year 1 were index prescription by orthopedists
and not having undergone baseline BMD measurementbefore pharmacologic treatment for osteoporosis was
initiated. However, male subjects with RA were more
likely to have good compliance.
Compliance with medications used to treat or prevent
osteoporosis ranged from 34% to 94.6% at 1 year [27-31]
and 27% to 43% at 2 years [27,32]. However, the results
were subject to various definitions of compliance, and
female gender, bisphosphonate users and different study
populations were mainly focused on in each investiga-
tion [28,30]. Our data examined adherence not only
among male users of oral (daily and weekly) bisphos-
phonates, but also among male users of calcitonin.
Hansen et al. [14] reported that adherence to alendro-
nate in male veterans during the first 12 and 24 months
of therapy was 59% and 54%, respectively. A small series
study by Cevikoi A [15] demonstrated that full compli-
ance rates for the 1- and 3-year periods were 49.4% and
17.9%, respectively. The results of our investigation of
good compliance at the first year were similar to those
of most studies on postmenopausal women [14,32,33].
However, at year 2, good compliance in our cohort was
37.5%, which was lower than that in Hansen’s study [14].
A recent study on compliance among male subjects
reported that the 1-year good compliance (MPR ≥ 80%)
and persistence rates were 91% and 39.7%, respectively
[21]. They attributed the relatively high 1-year good
compliance rate to (1) including both new and existing
patients with at least 3 prescriptions; (2) the specific ethnic
group (a Dutch population); and (3) reimbursement of all
osteoporosis medications [21]. That was in contrast to our
study population, which had fewer than 3 prescriptions
and limited reimbursement for fracture subjects.
Previous investigations that were mainly focused on
bisphosphonate users demonstrated 1-year PRs ranging
from 24% to 74.8% [15,21,34-36]. In our study, the per-
sistence curve revealed an obvious drop (38.3%) in the
first year, but a less prominent (19.5%) drop in the sec-
ond year among those subjects persistent with their
medication at the end of the first year. This was similar
to the observation in several studies on adherence to
anti-osteoporosis agents among postmenopausal women
[37-39]. The previous study had demonstrated that in-
creasing age, pain, no use of diagnostic tests, and male
showed a positive effect on the probability of quitting
the anti-osteoporotic medication [40]. It also suggests
that improving adherence in the first year is essential to
achieving a better therapeutic response for either gender.
Therefore, the factors related to inadequate compliance
for each year were investigated in the current study.
Possible factors affecting medication adherence have
been reviewed in the literature and include side effects,
smoking behavior, surveying for bone density during
therapy, educational status, social support, marital sta-
tus, and income [14,15,41]. However, these factors were
Table 2 Factors associated with poor-compliance in subjects of total cohort and subgroup
Total subjects at year 1 (n = 333) Subgroup subjects at year 2 (n = 174)a
Risk factors n (%) Univariate analysis Multivariate analysis n (%) Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Age 1.03 (1.01-1.05) 0.007 1.02 (0.99-1.05) 0.132 0.97 (0.94-0.99) 0.045 0.97 (0.94-1.01) 0.100
First prescribed by
Rheumatologist 55 (34.6) 1.0 (referent) 1.0 (referent) 24 (48.0) 1.0 (referent) 1.0 (referent)
Orthopedist 64 (40.3) 2.67 (1.58-4.53) 0.000 2.30 (1.26-4.22) 0.007 13 (26.0) 1.38 (0.60-3.14) 0.447 1.52 (0.58-3.96) 0.394
Others 40 (25.2) 1.19 (0.70-2.03) 0.525 1.12 (0.62-2.05) 0.709 13 (26.0) 0.85 (0.39-1.86) 0.679 0.86 (0.35-2.14) 0.746
DXA 13 (8.2) 0.52 (0.32-0.85) 0.008 0.51 (0.28-0.93) 0.029 17 (34.0) 0.97 (0.49-1.94) 0.932 0.94 (0.39-2.26) 0.895
Vertebroplasty 5 (3.1) 0.91 (0.27-3.04) 0.877 0.59 (0.15-2.30) 0.450 1 (2.0) 0.49 (0.06-4.27) 0.515 0.71 (0.07-7.08) 0.769
Fracture site
Spine fracture 131 (82.4) 1.40 (0.81-2.40) 0.225 1.54 (0.45-5.29) 0.489 36 (72.0) 0.68 (0.32-1.45) 0.320 0.37 (0.05-2.95) 0.345
Hip fracture 27 (17.0) 1.49 (0.81-2.76) 0.204 1.21 (0.41-3.54) 0.731 7 (14.0) 1.28 (0.48-3.36) 0.620 0.47 (0.06-3.50) 0.457
Others fracture 13 (8.2) 1.85 (0.75-4.58) 0.185 1.88 (0.69-5.10) 0.216 3 (6.0) 1.52 (0.35-6.61) 0.577 1.16 (0.22-6.23) 0.863
Tobacco useb 1 (0.6) – 0.477 0.00 (0.00) 1.000 0 (0) – – – –
Alcohol use 1 (0.6) 1.10 (0.07-17.65) 0.949 0.00 (0.00) 1.000 1 (2.0) 4.09 (0.00) 1.000 1.37 (0.00) 1.000
Malignancy 11 (6.9) 1.00 (0.43-2.34) 0.994 0.98 (0.39-2.45) 0.960 3 (6.0) 0.82 (0.21-3.15) 0.767 0.78 (0.19-3.27) 0.734
Cardiac disease 32 (20.1) 1.94 (1.06-3.56) 0.032 1.87 (0.93-3.75) 0.079 7 (14.0) 1.39 (0.52-3.72) 0.512 1.79 (0.58-5.49) 0.311
Respiratory disease 19 (11.9) 1.34 (0.66-2.71) 0.413 1.22 (0.57-2.63) 0.610 4 (8.0) 0.81 (0.25-2.65) 0.729 0.72 (0.20-2.56) 0.611
Neuropsychiatric
disease
30 (18.9) 1.21 (0.69-2.14) 0.505 0.89 (0.47-1.70) 0.732 6 (12.0) 0.63 (0.24-1.67) 0.354 0.68 (0.23-2.02) 0.485
Chronic kidney
disease
12 (7.5) 1.34 (0.56-3.19) 0.509 1.35 (0.51-3.58) 0.548 2 (4.0) 0.60 (0.12-2.95) 0.533 0.66 (0.12-3.62) 0.636
Endocrine/metabolic 29 (18.2) 1.54 (0.85-2.81) 0.157 1.81 (0.90-3.64) 0.095 6 (12.0) 0.92 (0.34-2.51) 0.871 0.82 (0.26-2.60) 0.734
Hypertension 49 (30.8) 0.83 (0.52-1.31) 0.411 0.62 (0.37-1.06) 0.083 21 (42.0) 1.52 (0.77-2.99) 0.224 1.62 (0.77-3.43) 0.207
Rheumatoid arthritis 3 (1.9) 0.22 (0.06-0.78) 0.011 0.19 (0.04-0.81) 0.025 4 (8.0) 0.99 (0.30-3.32) 0.989 0.81 (0.17-3.89) 0.790
Hepatobiliary disease 6 (3.8) 0.42 (0.16-1.10) 0.075 0.44 (0.16-1.25) 0.124 2 (4.0) 0.36 (0.08-1.64) 0.185 0.45 (0.09-2.33) 0.340
Steroid use 21 (13.2) 0.73 (0.40-1.34) 0.307 1.48 (0.68-3.22) 0.320 10 (20.0) 1.30 (0.56-3.02) 0.541 1.02 (0.31-3.29) 0.980
OR odds ratio, CI confidence interval, Serum creatinine >1.4 mg/dl; aSubjects with MPR ≥ 80% at year 1; bNo one smoked, so the factor cannot be estimated; All
comparisons denote present vs. absent.
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on several characteristics of male subjects, e.g., jobs, life-
style, and educational levels, were not collected, which
potentially may be related to compliance with therapy in
the current study. Hence, our finding suggests that cer-
tain unidentified factors pertaining to male subjects may
be related to poor compliance, as demonstrated by pre-
vious studies.
In our study, patients of orthopedists were more likely
to discontinue osteoporosis medications at year 1 than
those seeing rheumatologists. This is in agreement with
a previous study showing that patients of orthopedists
were more likely to discontinue their medications than
the patients of rheumatologists and general practitioners,
probably due to a lack of adequate doctor motivation [42].
Physician specialty was significantly associated with adher-
ence to treatment guidelines [43]. Ideguchi et al. found
that patients of gynecologists or rheumatologists were
more likely to continue bisphosphonates than patients oforthopedists or other specialists [44]. BMD measurement
was highest among patients treated with glucocorticoids
prescribed by rheumatologists [45]; therefore, rheumatolo-
gists often had more opportunities to prescribe anti-
osteoporotic medications to prevent or treat GIOP than
other specialties. We speculated from our study results
that having follow-up for each long-term prescription by a
physician specializing in osteoporosis (especially an intern-
ist, for example, a rheumatologist) with feedback to the
patients may improve the patient-physician relationship
and adherence.
A lack of DXA at baseline (before therapy) was an-
other factor of 1-year poor compliance in our study.
Similar observations were also reported in Pickney’s [46]
and Solomon’s studies [29]. In contrast, Hansen et al.
showed that non-adherence to oral anti-osteoporosis
medications among men was associated with a lack of
measurements of bone mass during alendronate therapy,
but not before therapy [14]. It has been demonstrated
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to higher treatment rates and better adherence to treat-
ment [46]. Adherers who have undergone bone mass
measurements at baseline might be more aware of their
disease course and of the risks of subsequent or recur-
rent fractures than non-adherers.
Richards et al. observed that non-adherence to
bisphosphonates was common in a cohort of RA pa-
tients who were veterans in the United States [47]. In
contrast, RA patients in our study were more likely to
continue osteoporosis medications. We would expect
good compliance with osteoporosis medications in pa-
tients with RA because of the awareness of physicians
and patients about the negative effects of glucocorticoids
on bone. Most patients with RA may need to receive ster-
oid treatment in clinical practice, which puts them at high
risk for GIOP. Rossini et al. demonstrated positive associ-
ations between glucocorticoid and anti-inflammatory
treatment and compliance with osteoporosis medications
[42]. Although steroid users did not have a higher compli-
ance rate in the current study, other determining factors
associated with adherence among osteoporotic RA male
patients could be further explored in the future.
There are several limitations in our study. (1) It is un-
known if patients actually took the dispensed drug. We
assumed that patients who obtain prescription refills do
take their medications based on chart review. In
addition, in Taiwan, patients can obtain 2 to 3 prescrip-
tions each visit for a stable disease. We were unable to
ascertain whether patients obtained refills at outside phar-
macies. As a result, adherence may be overestimated.
(2) We determined adherence based on the number of
refills. Therefore, whether the drug was delivered cor-
rectly at the correct time of day or in appropriate doses
is unknown. (3) Due to the retrospective study design,
some information obtained from chart reviews may be
not complete and the data collection may be subjective.
(4) We did not collect data on the side effects of anti-
osteoporotic regimens from the chart reviews, which
may actually have influenced adherence. (5) Our sample
size was relatively small. Therefore, we may not have
determined all factors associated with non-adherence
among male patients. (6) Finally, patient characteristics
linked to adherence from databases at a single medical
center probably were not universally applicable to men
treated by community-based practitioners.
However, our study has some advantages. (1) We
reviewed medical charts to determine patient variables
associated with adherence, information that is often not
acquired in claims databases. (2) Most studies reported
on the adherence mainly of postmenopausal women; we
targeted men who are not normally enrolled or included
in osteoporosis adherence studies exclusively. (3) We an-
alyzed adherence over a period of 2 years and identifiedpatient-specific factors of poor adherence on a year-by
-year basis. This information can serve as a reminder to
prescribers year by year to improve adherence.
Conclusions
Our study indicates that men with osteoporosis are not
optimally treated in daily clinical practice in southern
Taiwan. Starting prescriptions by orthopedists signifi-
cantly contributed to non-compliance, and men with RA
and baseline bone mass measurements were less likely
to have poor compliance. Identifying risk factors associ-
ated with non-adherence may help healthcare profes-
sionals improve adherence.
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